Answers are grounded in this paper and cite their sources.
The liver imaging reporting and data system (LI-RADS) CT/MRI treatment response assessment (TRA) provides a standardized framework for evaluating treatment response following loco-regional therapy for hepatocellular carcinoma (HCC). Initially introduced in 2017, it was revised in 2024 to reflect advances in research. The updated LI-RADS CT/MRI TRA v2024 presents a bifurcated algorithm based on the mechanisms underlying loco-regional therapy and introduces distinct assessment criteria with which to evaluate treatment response after radiation therapy. Furthermore, ancillary imaging features, including diffusion restriction and mild-to-moderate T2 hyperintensity, have been incorporated as optional adjuncts to refine the assessment of viable tumors. The effective implementation of the LI-RADS CT/MRI TRA v2024 is anticipated to enhance treatment response assessment following loco-regional therapy for HCC. Further research is encouraged in order to ensure the continuous refinement and optimization of the assessment criteria.
No takes yet. Share an insight, caveat, or question.
Shin et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: